A potential “vaccine” for cancer has shown positive results in a recent clinical trial involving almost a dozen lymphoma patients, CNBC reports.
Researchers at Mount Sinai Hospital in New York tested an experimental treatment on 11 patients with lymphoma, and published their findings in the journal Nature Medicine on Monday. The treatment’s success led to another clinical trial in March on patients with lymphoma, breast cancer, and head-and-neck cancer. According to researchers, some of these patients even went into full remission for months or years.
Dr. Joshua Brody, the director of the lymphoma immunotherapy program and the lead author of the study, told CNBC that the treatment “has broad implications for multiple types of cancer. This method could also increase the success of other immunotherapies such as checkpoint blockade.”
Although the treatment doesn’t prevent cancer like other vaccines, researchers refer to it as one because it makes a body’s immune system fight the disease.
“It’s definitely proof of concept, but larger studies are definitely needed and additional strategies to try to get more than three out of 11 patients to respond,” said Dr. Eric Jacobsen, the clinical director of the lymphoma program at the Dana-Farber Cancer Institute. CNBC notes that Jacobsen is developing his own approach to creating a lymphoma vaccine.
© 2024 Newsmax. All rights reserved.